TriApex

TriApex (鼎泰药研集团) is a preclinical research services provider backed by Qiming Venture Partners, which describes it in its 2025 weekly portfolio roundups as a portfolio company delivering "compliant, high-quality, and efficient" non-clinical research services . Its work surfaces mainly through drug-development partners: it was the principal non-clinical collaborator on the GA001 ophthalmology project, contributing project evaluation experience in eye-disease programs , and its partners' candidates include 鼎乐新为's Class 1 new drug DNV001 injection, which received CDE clearance to proceed to clinical trials , and SynerK's siRNA candidate SNK-2726, cleared by both China's CDE and the US FDA . Note that elsewhere's corpus covers TriApex only through these Qiming updates as of 2025 — details like founding history, scale, or financing aren't covered.